Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Atriplex wrightii pollen is a non-standardized allergenic extract derived from the pollen of the Atriplex wrightii plant, also known as Wright's saltbush or annual saltbush. [2, 7] Manufactured by Greer Laboratories, Inc. (a subsidiary of Stallergenes Greer), the extract is used for both the diagnosis and treatment of allergies specific to this pollen. [3, 4, 6] For diagnosis, it is applied via percutaneous (prick) or intradermal skin tests to confirm sensitivity. [4] For treatment, it is administered as subcutaneous immunotherapy (allergy shots) to desensitize the immune system and reduce allergic symptoms in patients with a confirmed allergy. [4, 14, 15] The therapy works by repeatedly exposing the patient to the allergen to induce immunologic tolerance. [14, 15]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Atriplex wrightii pollen.